Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Combined With Donafenib in Advanced HCC
NCT04503902Phase 2Unknown
- Sponsor
- Zelgen
- Start
- Oct 2020
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of donafenib, toripalimab in hepatocellular carcinoma (HCC), sponsored by Zelgen. Status: unknown.
02
Drugs
donafenibtoripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04503902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04503902.